Effect of a GLP-1 mimetic on the insulin response to oral sugar testing in horses.
Authors: Stefanovski Darko, Robinson Mary A, Van Eps Andrew
Journal: BMC veterinary research
Summary
# Editorial Summary Insulin dysregulation remains the primary driver of laminitis risk in horses, yet therapeutic options remain limited, prompting investigation into glucagon-like peptide-1 (GLP-1) agonists as a potential management strategy. Stefanovski and colleagues conducted a randomised crossover trial in six horses (four with mild insulin dysregulation, two with normal regulation) comparing a single subcutaneous dose of the GLP-1 mimetic exenatide against a control, administered 30 minutes before an oral sugar challenge, with blood sampling over four hours to assess postprandial glucose, insulin, and insulin sensitivity metrics. Exenatide produced a clinically meaningful 20% reduction in the insulin area-under-the-curve response (mean reduction of 2,673 μU·min/ml, P = 0.003) and approximately tripled estimated insulin sensitivity compared with the control arm—improvements that occurred through enhanced whole-body insulin sensitivity rather than altered glucose absorption. These findings suggest GLP-1 agonists warrant further investigation as a pharmacological intervention for horses with insulin dysregulation, particularly given the significant reduction in hyperinsulinaemia, though larger, longer-term studies are needed to establish efficacy, optimal dosing schedules, and safety profiles before clinical adoption. Farriers, veterinarians, and nutritionists managing at-risk horses should remain alert for emerging evidence on GLP-1 therapeutics, as this class of medication could substantially improve laminitis prevention strategies in insulin-dysregulated populations.
Read the full abstract on PubMed
Practical Takeaways
- •GLP-1 agonists like exenatide show promise as a pharmacological intervention to reduce laminitis risk by improving insulin metabolism in dysregulated horses
- •A single dose of exenatide meaningfully lowered insulin spikes following carbohydrate intake, which could translate to reduced laminitis trigger in susceptible animals
- •This research supports further investigation into GLP-1 mimetics as a therapeutic option, though clinical efficacy and dosing protocols for field use require confirmation in larger studies
Key Findings
- •Exenatide reduced postprandial insulin AUC by 20% (from 11,989 to 9,316 µU·min/ml, P=0.003)
- •Exenatide increased insulin sensitivity approximately threefold (from 1.93 to 7.49 × 10⁻⁴ µU/ml⁻¹·min⁻¹, P=0.02)
- •The improvement in insulin response was mediated by enhanced whole-body insulin sensitivity rather than reduced carbohydrate absorption